Why novel NRPS peptides are harder to source than you think

Sometimes a compound has a ring-shaped chemical group (called a heterocyclic moiety) that is very hard to build in the lab by normal methods. When that happens, it helps to ask: where did this molecule come from, and how did nature make it? A new preprint from a research team gives a close look at how bacteria build unusual peptides (short chains of amino acid building blocks) and where that process hits its limits. The compound at the center of the study carries a specific double-ring structure called a pyrrolizidine alkaloid at one end of its chain.

How NRPS assembly lines build what ribosomes cannot

Most proteins are made by tiny cell machines called ribosomes. Ribosomes read instructions from the cell and string together the 20 standard amino acids into chains. A different type of machine, called a non-ribosomal peptide synthetase (NRPS), skips the ribosome entirely. NRPSs are huge, multi-part enzyme machines. Think of them like a factory assembly line: each station picks one building block, activates it, and adds it to the growing chain. Because they work outside the normal rules, NRPSs can use unusual building blocks that ribosomes cannot, including mirror-image amino acids, chemically modified ones, and ring-bearing structures.

That flexibility has made NRPSs very interesting to scientists who want to engineer new compounds. The idea seems simple: swap out the part of the machine that picks a building block (called the adenylation domain), and you change what goes into the chain, producing a new product. In practice, though, most of the trouble comes at the end of the line.

The pyrrolizidine moiety and the enzyme that sculpts it

Pyrrolizidine alkaloids (PAs) are a family of chemicals built around a double-ring structure. Plants make them often, but bacteria can make their own versions. In bacteria, it takes two steps. First, the NRPS builds a peptide backbone, like laying the frame of a house. Then a second enzyme, called a Baeyer-Villiger monooxygenase (BVMO), goes to work. Think of the BVMO as a sculptor: it slips an oxygen atom into a carbon-carbon bond and reshapes the structure, squeezing that ring into the compact double-ring PA core. The compound studied here, pyrrolizixenamide, gets its PA group at the end of its chain through exactly this two-enzyme teamwork.

The Baeyer-Villiger reaction (adding oxygen to reshape a ring) is well known in chemistry. What is striking here is that one dedicated enzyme does in a single step what would take several separate lab reactions in total chemical synthesis. Nature often finds shortcuts that chemists envy.

Five successes, then the wall

Using several NRPS engineering strategies, the research team managed to build five new peptides, each with the PA double-ring at the end of its chain. Getting five different structural versions from one biosynthetic scaffold is real progress. But when they tried to build a larger set of variants, every attempt failed. Computer modeling and molecular docking (fitting virtual molecules together like puzzle pieces to see if they fit) showed exactly why.

The problem was the thioesterase (TE) domain, which sits at the very end of the NRPS assembly line. The TE domain acts like an exit gate: its job is to cut the finished peptide free and release it. But this particular TE domain is very picky. It will only release peptides that have two or fewer amino acids sitting in front of the PA group. Any peptide with a longer chain gets stuck. The peptide stays attached to the machine and is never released. The researchers call this a strict size limit, not just a slight slowdown. They say that future work will need to redesign or replace this exit gate with a less picky version before larger libraries of variants can be made.

This finding echoes a lesson that keeps coming up in NRPS research: changing which building blocks go in earlier in the assembly line is not enough if the exit gate has its own strict rules. Every new peptide the upstream stations build still has to pass through that gate.

What this means when you're sourcing an unusual scaffold

For researchers who work with peptides that carry ring-shaped or alkaloid-derived chemical groups, understanding the limits of the biosynthetic machinery helps you judge what a vendor is actually offering. If a compound needs a structural variant that current NRPS engineering cannot produce, that peptide was either made by total chemical synthesis (which has its own cost and purity profile) or by a biosynthetic process that may not be well understood. If a vendor cannot explain the synthesis route for an unusual scaffold, it is worth asking harder questions.

When checking documentation for any novel biosynthetically made peptide, the same basic checklist applies no matter how unusual the scaffold:

• COA (certificate of analysis) with HPLC purity percentage (a lab test that separates and measures components in a sample) and the actual chromatogram (the printed graph), not just a written number
• Synthesis route specification (biosynthetic, semi-synthetic, or total synthesis)
• Molecular weight confirmation by mass spec (a tool that measures the exact mass of a molecule)

Reconstituting (dissolving) PA-bearing peptides follows the same basic steps as any research peptide. However, the double-ring structures made by oxidative reshaping (adding oxygen to contract a ring) can break down more easily when exposed to oxygen in solution. Working in smaller portions (aliquots), limiting the number of freeze-thaw cycles, and keeping reconstituted samples at the cooler end of your storage temperature range all help reduce how long the sample sits in a potentially damaging environment. Purity matters especially here, because the biosynthetic route to these compounds is already tightly constrained. The margin for undeclared impurities in a small-batch novel scaffold is narrower than you might expect.

Prompted by this coverage at bioRxiv →

Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators

Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.

Frequently asked questions

Why does NRPS engineering fail to produce large libraries of peptide variants?

The thioesterase (TE) domain at the assembly-line terminus enforces a strict size limit: peptides with more than two residues upstream of the pyrrolizidine group remain tethered and are never released, halting production regardless of upstream changes.

What is the role of the thioesterase domain in an NRPS assembly line?

The TE domain acts as an exit gate at the end of the NRPS assembly line, catalyzing cleavage and release of the finished peptide. When the TE domain is substrate-selective, it becomes the primary bottleneck limiting structural diversity of accessible products.

How do bacteria build pyrrolizidine alkaloid moieties in NRPS peptides?

Bacteria use a two-enzyme strategy: the NRPS first assembles the peptide backbone, then a Baeyer-Villiger monooxygenase inserts an oxygen into a carbon-carbon bond, reshaping the ring system into the compact pyrrolizidine alkaloid bicyclic core in a single enzymatic step.

What the research community gets wrong about NRPS peptides and pyrrolizidine alkaloid scaffolds

Working with peptides that carry an unusual ring group tends to attract a few assumptions that do not hold up at the bench. A few worth checking before you order or reconstitute a vial.

• Swapping the building-block picker is not the whole story. A common belief is that changing the adenylation domain (the part that chooses each amino acid) is enough to make any new variant. In practice the thioesterase domain (the exit gate at the end of the assembly line) has its own size rules and can refuse to release longer chains, so many designed variants are never produced at all.
• "Novel scaffold" does not mean it came from bacteria. A rare ring such as a pyrrolizidine core can be made by total chemical synthesis instead of a biosynthetic route. That changes the impurity profile you may see on your own analysis, so the synthesis route is worth confirming rather than assuming.
• The double-ring is not as sturdy as a plain peptide backbone. Pyrrolizidine cores are built by inserting oxygen to reshape a ring (a Baeyer-Villiger step). Structures made this way can break down more readily once oxygen reaches them in solution, so a sample that looked fine dry can drift after reconstitution.
• A purity number on paper is not the same as data. For an unusual scaffold, a written percentage on a certificate of analysis is easy to state and hard to check. The actual chromatogram plus a mass spec result tells you far more about what is really in the vial.

From our bench: If you have handled a peptide carrying a pyrrolizidine or other oxygen-reshaped ring, we would like your real notes. How did a reconstituted aliquot hold up across repeated freeze-thaw cycles, and did you see any change in the HPLC trace or a color shift in solution over the days you stored it? Share the storage temperature you used and what you actually observed (no estimates, just what your own records show) and we will fold verified reader reports into a future update.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Einsiedler M, et al. Product Selectivity in Baeyer-Villiger Monooxygenase-Catalyzed Bacterial Alkaloid Core Structure Maturation. J Am Chem Soc. 2024. PMID 38829274
5. Süssmuth RD, Mainz A. Nonribosomal Peptide Synthesis - Principles and Prospects. Angew Chem Int Ed Engl. 2017. PMID 28323366
6. Pyrrolizidine (parent bicyclic core), PubChem CID 12558, National Library of Medicine